NEW YORK (GenomeWeb) – Meridian Bioscience today released its revenue and earnings per share guidance for fiscal year 2015, coming in below Wall Street expectations.

The Cincinnati-based diagnostics and life science research tools firm, however, reaffirmed its FY 2014 revenue guidance of $190 million to $195 million, and its earnings-per-share guidance of between $.85 and $.90, both within analysts' consensus estimates of $191.6 million in revenues and EPS of $.86. Meridian's fiscal year ends on Sept. 30.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: investigation into the genetics of medulloblastoma, and more

Researchers examine the gap in funding between researchers and research institutions, ScienceInsider reports

By sequencing two ancient dog genomes, researchers from the US and Germany suggest that dogs were domesticated in a single event, the Washington Post reports.

In Genome Research this week: population dynamics of E. coli infection, lncRNA expression changes in macaque aging, and more.